IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours

Amary, M Fernanda, Bacsi, Krisztian, Maggiani, Francesca, Damato, Stephen, Halai, Dina, Berisha, Fitim, Pollock, Robin, O'Donnell, Paul +8 more·2011·The Journal of Pathology
DOI 10.1002/path.2913

Cited by (1,000)

Items 501–600 of 1,000

  1. Distribution of copy number variations and rearrangement endpoints in human cancers with a review of literature
    Golrokh Mirzaei, Ruben C. Petreaca · 2021 · Mutation research. Fundamental and molecular mechanisms of mutagenesis
  2. Can MR imaging challenge the commonly accepted theory of the pathogenesis of solitary enchondroma of long bone?
    Hassan Douis, A. Mark Davies, Steven James, Lars‐Gunnar Kindblom, Robert John Grimer, Karl Johnson · 2012 · Skeletal Radiology
  3. Ovarian cellular fibroma harbouring an isocitrate dehydrogenase 1 (1 DH 1) mutation in a patient with Ollier disease: evidence for a causal relationship
    Sarah L Kenny, Kaushik Patel, Anna Humphries, Michael Davis, Adrienne Margaret Flanagan, Wilson Glenn McCluggage · 2013 · Histopathology
  4. Hereditäre Knochentumoren
    Daniel Baumhoer · 2017 · Der Pathologe
  5. hTERT promoter mutations in chondrosarcomas associate with progression and disease-related mortality
    Yingbo Lin, Nelly Seger, Yi Chen, Asle Charles Hesla, Johan Wejde, Mehran Ghaderi, Panagiotis Tsagkozis, Olle Larsson, Felix Haglund · 2018 · Modern Pathology
  6. Maffucci syndrome complicated by three different central nervous system tumors sharing an IDH1 R132C mutation: case report
    Takahide Nejo, Shota Tanaka, Masako Ikemura, Masashi Nomura, Shunsaku Takayanagi, Masahiro Shin, Tetsuo Ushiku, Junji Shibahara, Nobuhito Saito, Akitake Mukasa · 2019 · Journal of neurosurgery
  7. Role of immunotherapy in chondrosarcoma: A case report and review of the literature
    Cohen-Nowak, Adam J., Dressler, Danielle B., Rock, Adam, Mojica, Katherine, Woo, Doni, Zuckerman, Lee M., Chow, Warren, Agulnik, Mark · 2023 · Therapeutic Advances in Medical Oncology
  8. Deciphering the multifaceted roles and clinical implications of 2-hydroxyglutarate in cancer
    Jie Hao, Ziyi Huang, Siyue Zhang, Kefan Song, Juncheng Wang, Chao Gao, Zhiqing Fang, Ning Zhang · 2024 · Pharmacological Research
  9. IDH1 Mutation Induces HIF-1α and Confers Angiogenic Properties in Chondrosarcoma JJ012 Cells
    Xiaoyu Hu, Luyuan Li, Josiane E. Eid, Chao Liu, Jinming Yu, Jinbo Yue, Jonathan C. Trent · 2022 · Disease Markers
  10. Challenges for the development of mutant isocitrate dehydrogenases 1 inhibitors to treat glioma
    Qing-Xin Wang, Peng-Yu Zhang, Qingqing Li, Zhen‐Jiang Tong, Shao‐Peng Yu, Yan‐Cheng Yu, Yan‐Cheng Yu, Ning Ding, Xue-Jiao Leng, Liang Chang et al. · 2023 · European Journal of Medicinal Chemistry
  11. Targeting DNA Methylation Machinery in Pediatric Solid Tumors
    Camilla Cristalli, Katia Scotlandi · 2024 · Cells
  12. The Biology and Management of Cartilaginous Tumors: A Role For Targeting Isocitrate Dehydrogenase
    Gabriel Tinoco, Breelyn Ann Wilky, Ana Cristina Paz-Mejia, Andrew Eric Rosenberg, Jonathan C. Trent · 2015 · American Society of Clinical Oncology Educational Book
  13. Metabolic alteration in tumorigenesis
    Hui Yang, Yue Xiong, Kun‐Liang Guan · 2013 · Science China Life Sciences
  14. Discovery and structure-activity-relationship study of novel imidazole cyclopropyl amine analogues for mutant isocitric dehydrogenase 1 (IDH1) inhibitors
    Qiangang Zheng, Ziqi Chen, Huixin Wan, Shuai Tang, Yan Ye, Yuan Xu, Lei Jiang, Jian Ding, Meiyu Geng, Min Huang et al. · 2018 · Bioorganic & Medicinal Chemistry Letters
  15. Single-Cell Metabolomics in Hematopoiesis and Hematological Malignancies
    Fengli Zuo, Jing Yu, Xiujing He · 2022 · Frontiers in Oncology
  16. Up-regulated isocitrate dehydrogenase 1 suppresses proliferation, migration and invasion in osteosarcoma: In vitro and in vivo
    Xiang Hu, Yang Liu, Chunxia Qin, Zhenyu Pan, Jun Luo, Aixi Yu, Zhen Cheng · 2013 · Cancer Letters
  17. Bridging Cancer Biology with the Clinic: Comprehending and Exploiting IDH Gene Mutations in Gliomas
    Ourania Romanidou, Vassiliki Kotoula, George Fountzilas · 2018 · Cancer Genomics & Proteomics
  18. IDH1 immunohistochemistry reactivity and mosaic IDH1 or IDH2 somatic mutations in pediatric sporadic enchondroma and enchondromatosis
    Essia Saïji, Fabienne Gumy‐Pause, Pierre Lascombes, Christelle Cerato Biderbost, Nathalie Lin Marq, Margaret Berczy, Laura Merlini, Anne‐Laure Rougemont · 2019 · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin
  19. Genetic drivers and cells of origin in sarcomagenesis
    Sarmishta Kannan, Ian C. Lock, Benjamin B. Ozenberger, Kevin B. Jones · 2021 · The Journal of Pathology
  20. Synthesis of [1‐13C‐5‐12C]‐alpha‐ketoglutarate enables noninvasive detection of 2‐hydroxyglutarate
    Natsuko Miura, Chandrasekhar Mushti, Deepak Sail, Jenna E. AbuSalim, Kazutoshi Yamamoto, Jeffrey Brender, Tomohiro Seki, Deyaa I. AbuSalim, Shingo Matsumoto, Kevin A. Camphausen et al. · 2021 · NMR in Biomedicine
  21. An Enzymatic Biosensor for the Detection of D-2-Hydroxyglutaric Acid in Serum and Urine
    Bo Wu, Zehua Li, Zepeng Kang, Chunling Ma, Haiyan Song, Fuping Lu, Zhiguang Zhu · 2022 · Biosensors
  22. Therapeutic targeting of chromatin alterations in leukemia and solid tumors
    Florian Perner, Tobias Berg, D. Sasca, Sophie-Luise Mersiowsky, Jayant Y. Gadrey, Johanna Thomas, Michael W. M. Kühn, M. Lübbert · 2025 · International Journal of Cancer
  23. Molecular and Immune Mechanisms Governing Cancer Metastasis, Including Dormancy, Microenvironmental Niches, and Tumor-Specific Programs
    Dae Joong Kim · 2026 · International Journal of Molecular Sciences
  24. Dedifferentiated chondrosarcoma with minimal or small dedifferentiated component
    Carina Anja Dehner, Nolan Maloney, Behrang Amini, Jack W. Jennings, Douglas J. McDonald, Wei‐Lien Wang, John S.A. Chrisinger · 2022 · Modern Pathology
  25. A personalized medicine approach identifies enasidenib as an efficient treatment for IDH2 mutant chondrosarcoma
    Verónica Rey, Juan Tornín, Juan José Alba‐Linares, Cristina Robledo, Dzohara Murillo, Aida Rodríguez, Borja Gallego, Carmen Huergo, Cristina Viera, Alejandro Braña et al. · 2024 · EBioMedicine
  26. Generation of a novel monoclonal antibody WMab-1 specific for IDH2-R172W mutation
    Yukinari Kato, Mika Kato Kaneko · 2013 · Biochemical and Biophysical Research Communications
  27. 2‐Hydoxyglutarate: D/Riving Pathology in gLiomaS
    Daniel Richard Wahl, Sriram Venneti · 2015 · Brain Pathology
  28. A high-throughput analysis of the IDH1(R132H) protein expression in pituitary adenomas
    Olivera Casar‐Borota, Kristin Astrid Øystese, Magnus Sundström, Linea Cecilie Melchior, Vera M. POPOVIC · 2016 · Pituitary
  29. IDH1 mutation correlates with a beneficial prognosis and suppresses tumor growth in IHCC
    Jian Wang, Zhan-guo Zhang, Zeyang Ding, Wei Dong, Hui-fang Liang, Liang Chu, Bi-xiang Zhang, Xiaoping Chen · 2018 · Journal of Surgical Research
  30. Bad to the Bone: Emerging Approaches to Aggressive Bone Sarcomas
    Georgina Elizabeth Wood, Laurie A. Graves, Elyssa M. Rubin, Damon R. Reed, Richard F. Riedel, Sandra J. Strauss · 2023 · American Society of Clinical Oncology Educational Book
  31. Role of Genetic and Molecular Profiling in Sarcomas
    Scott Michael Norberg, Sujana Movva · 2015 · Current Treatment Options in Oncology
  32. Identification of a novel selective inhibitor of mutant isocitrate dehydrogenase 1 at allosteric site by docking-based virtual screening
    Fangxia Zou, Stefan Pusch, Jessica Eisel, Tianfang Ma, Qihua Zhu, Dawei Deng, Yueqing Gu, Yungen Xu, Andreas von Deimling, Xiaoming Zha · 2016 · RSC Advances
  33. Application of metabolomics in sarcoma: From biomarkers to therapeutic targets
    Li Min, Edwin Choy, Chongqi Tu, Francis John Hornicek, Zhenfeng Duan · 2017 · Critical Reviews in Oncology/Hematology
  34. Lack of evidence for substrate channeling or flux between wildtype and mutant isocitrate dehydrogenase to produce the oncometabolite 2-hydroxyglutarate
    Joseph P. Dexter, Patrick S. Ward, Tathagata Dasgupta, Aaron M. Hosios, Jeremy Gunawardena, Matthew G. Vander Heiden · 2018 · Journal of Biological Chemistry
  35. Clonality analysis and IDH1 and IDH2 mutation detection in both components of dedifferentiated chondrosarcoma, implicated its monoclonal origin
    Tingting Yang, Yueqing Bai, Jie Chen, Keyang Sun, Yanli Luo, Wentao Huang, Huizhen Zhang · 2020 · Journal of bone oncology
  36. Mutant Idh2 Cooperates with a NUP98-HOXD13 Fusion to Induce Early Immature Thymocyte Precursor ALL
    Liat Goldberg, Vijay Negi, Yang Jo Chung, Masahiro Onozawa, Yuelin Jack Zhu, Robert L. Walker, Rachel M. Pierce, Daxesh P. Patel, Kristopher W. Krausz, Frank J. Gonzalez et al. · 2021 · Cancer Research
  37. Metabolism of glioma and IDH1/IDH2 mutations
    Marta Rossetto, Pietro Ciccarino, Blandine Boisselier, Marianne Labussière, Marc Sanson · 2011 · Revue Neurologique
  38. Prevalence of the single-nucleotide polymorphism rs11554137 (IDH1105GGT) in brain tumors of a cohort of Italian patients
    Giorgia Acquaviva, Michela Visani, Dario de Biase, Gianluca Marucci, Enrico Franceschi, Alicia Tosoni, Alba Ariela Brandes, Kerry Jane Rhoden, Annalisa Pession, Giovanni Tallini · 2018 · Scientific Reports
  39. High TIL, HLA, and Immune Checkpoint Expression in Conventional High-Grade and Dedifferentiated Chondrosarcoma and Poor Clinical Course of the Disease
    Sjoerd P. F. T. Nota, Ahmad Al-Sukaini, Shalin S. Patel, Francesco Sabbatino, G. Petur Nielsen, Vikram Deshpande, Jennifer Holmes Yearley, Soldano Ferrone, Xinhui Wang, Joseph Hasbrouck Schwab · 2021 · Frontiers in Oncology
  40. Molecular and immunohistochemical testing of bone tumours: review and update
    S Krisztian Kovacs, Atikankul Manassaporn, G. Petur Nielsen, Yin Pun Hung · 2022 · Histopathology
  41. Prevalence and characteristics of benign cartilaginous tumours of the shoulder joint. An MRI-based study
    Johannes Nikolaus Woltsche, Maria Anna Smolle, Dieter H. Szolar, Marko Bergovec, Andreas Leithner · 2023 · Skeletal Radiology
  42. Clinico-Genomic Profiling of Conventional and Dedifferentiated Chondrosarcomas Reveals TP53 Mutation to Be Associated with Worse Outcomes
    Ryan A. Denu, Richard Kenneth Yang, Alexander J. Lazar, Shalin S. Patel, Valerae Olive Lewis, Jason Roszik, John Andrew Livingston, Wei‐Lien Wang, Kenna R Mills Shaw, Ravin Ratan et al. · 2023 · Clinical Cancer Research
  43. A single-cell atlas of conventional central chondrosarcoma reveals the role of endoplasmic reticulum stress in malignant transformation
    Zezhuo Su, Joshua W. K. Ho, Raymond Ching Hing Yau, Ying Lee Lam, Tony Wai Shek, Maximus C.F. Yeung, Hongtai Chen, Richard O. C. Oreffo, Kathryn S.E. Cheah, Kelvin Sin Chi Cheung · 2024 · Communications Biology
  44. Dedifferentiation in bone and soft tissue sarcomas: How do we define it? What is prognostically relevant?
    Sarah Dry · 2024 · Human Pathology
  45. Emerging drug profile: Krebs cycle and cancer: IDH mutations and therapeutic implications
    Sang Min Lee, Arielle Rose Urman, Pinkal M. Desai · 2019 · Leukemia & lymphoma/Leukemia and lymphoma
  46. An evaluation of enasidenib for the treatment of acute myeloid leukemia
    Maria Ilaria Del Principe, Giovangiacinto Paterno, Raffaele Palmieri, Luca Maurillo, Francesco Buccisano, Adriano Venditti · 2019 · Expert Opinion on Pharmacotherapy
  47. Benign Cartilage-forming Tumors
    Darcy A. Kerr, Nicole A. Cipriani · 2021 · Surgical pathology clinics
  48. Tumeurs des tissus mous avec fusion du gène FN1 (Fibronectine 1)
    Corinne Bouvier, Hugo Nihous, Nicolas Macagno · 2022 · Annales de Pathologie
  49. Imaging Features of Periosteal Chondroma Manifesting as a Subcutaneous Mass in the Index Finger
    Hidetomo Kosaka, Jun Nishio, Taiki Matsunaga, Mikiko Aoki, Hiroshi Iwasaki, Masatoshi Naito · 2014 · Case Reports in Orthopedics
  50. An orthotopic mouse model for chondrosarcoma of bone provides an in vivo tool for drug testing
    Jolieke G. van Oosterwijk, Jacqueline R. M. Plass, Daniëlle Meijer, Ivo Que, Marcel Karperien, Judith V.M.G. Bovée · 2014 · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin
  51. Oncogenic potential of IDH1R132C mutant in cholangiocarcinoma development in mice
    Ning Ding · 2016 · World Journal of Gastroenterology
  52. Ollier disease with anaplastic astrocytoma: A review of the literature and a unique case
    Jonathan Pishoi Nakhla, Srikanth Gajavelli, Rani Nasser, Reza Yassari, Karen M. Weidenheim, Jerome J. Graber · 2016 · Surgical Neurology International
  53. Investigating the Influence of Hotspot Mutations in Protein–Protein Interaction of IDH1 Homodimer Protein: A Computational Approach
    D. Thirumal Kumar, P. Sneha, Jennifer Uppin, S. Usha, C. George Priya Doss · 2017 · Advances in protein chemistry and structural biology
  54. Metabolomics in the Diagnosis of Pheochromocytoma and Paraganglioma
    Trisha Dwight, Edward Kim, Talia Novos, Roderick John Clifton-Bligh · 2019 · Hormone and Metabolic Research
  55. Gene of the month: IDH1
    Cassandra Bruce‐Brand, Dhirendra Govender · 2020 · Journal of Clinical Pathology
  56. The Distribution and Significance of IDH Mutations in Gliomas
    Marta Mellai, Valentina Caldera, Laura Annovazzi, Davide Schiffer · 2013 · InTech eBooks
  57. Impending Impact of Molecular Pathology on Classifying Adult Diffuse Gliomas
    Robert J.B. Macaulay · 2015 · Cancer Control
  58. Impairment of Tricarboxylic Acid Cycle (TCA) Cycle in Alzheimer's Disease: Mechanisms, Implications, and Potential Therapies
    Gudimetla Susmitha Mohan, Rahul Kumar · 2025 · Aging and Disease
  59. The Production of Oxalate by Aspergillus niger under Different Lead Concentrations
    Yijun Huang, Liangliang Zhang, Shijia Yuan, Wenpei Liu, Chaochun Zhang, Da Tian, Xinxin Ye · 2023 · Agronomy
  60. Metabolic reprogramming in osteosarcoma
    Yulu Shi, Xiaohan Yue, Qing Luo · 2023 · Pediatric Discovery
  61. Malignant Cartilage-Forming Tumors
    Meera Hameed · 2021 · Surgical pathology clinics
  62. IDH Mutations Are Potentially the Intrinsic Genetic Link among the Multiple Neoplastic Lesions in Ollier Disease and Maffucci Syndrome: A Clinicopathologic Analysis from a Single Institute in Shanghai, China
    Chunyan Chen, Jian Li, Ting Jiang, Juan Tang, Zhichang Zhang, Yanli Luo, Xinpei Wang, Keyang Sun, Zhiming Jiang, Juan Zhou et al. · 2022 · Diagnostics
  63. Does PARP Inhibition Sensitize Chondrosarcoma Cell Lines to Chemotherapy or Radiotherapy? Results From a Three-dimensional Spheroid Cell Model
    Ieva Palubeckaitė, Sanne Venneker, Brendy E.W.M. van den Akker, Inge H. Briaire‐de Bruijn, Judith V.M.G. Bovée · 2022 · Clinical Orthopaedics and Related Research
  64. Tailored therapy in diffuse gliomas: using molecular classifiers to optimize clinical management.
    Jennie Webster Taylor, Andrew S Chi, Daniel P. Cahill · 2013 · PubMed
  65. IDH Mutation Analysis in Ewing Sarcoma Family Tumors
    Kiyong Na, Byeong‐Joo Noh, Ji‐Youn Sung, Youn Wha Kim, Eduardo Santini Araujo, Yong-Koo Park · 2015 · Journal of Pathology and Translational Medicine
  66. Quantitative Imaging of D-2-Hydroxyglutarate in Selected Histological Tissue Areas by a Novel Bioluminescence Technique
    Nadine Voelxen, Stefan Walenta, Martin Andreas Proescholdt, Katja Dettmer, Stefan Pusch, Wolfgang Mueller‐Klieser · 2016 · Frontiers in Oncology
  67. Metabolic Enzymes in Sarcomagenesis: Progress Toward Biology and Therapy
    Luyuan Li, Josiane E. Eid, Ana Cristina Paz, Jonathan C. Trent · 2017 · BioDrugs
  68. Notochordal Tumors
    Roberto Tirabosco, Paul O’Donnell, Adrienne Margaret Flanagan · 2021 · Surgical pathology clinics
  69. IDH mutation and cancer stem cell
    Yang Zhang, Yang Liu, Fengchao Lang, Chunzhang Yang · 2022 · Essays in Biochemistry
  70. Resveratrol in management of bone and spinal cancers
    Gang Chen, Hong Xia, Zhiguo Zhang, Hailiang Yu · 2017 · Natural Product Research
  71. Molecular profiling of different glioma specimens from an Ollier disease patient suggests a multifocal disease process in the setting of IDH mosaicism
    Char Loo Tan, Balamurugan A. Vellayappan, Bingcheng Wu, Tseng Tsai Yeo, Roger E. McLendon · 2018 · Brain Tumor Pathology
  72. Something Old and Something New About Molecular Diagnostics in Gliomas
    Craig Horbinski · 2012 · Surgical pathology clinics
  73. Metabolic Rewiring in Adult-Type Diffuse Gliomas
    Jong‐Whi Park · 2023 · International Journal of Molecular Sciences
  74. Discovery of novel natural-product-derived mutant isocitrate dehydrogenases 1 inhibitors: Structure-based virtual screening, biological evaluation and structure-activity relationship study
    Tieling Xu, Junya Yang, Dong‐Sheng Li, Mahesh Challa, Cheng Zou, Ping Deng, Shaolin Zhang, Biao Xu · 2024 · European Journal of Medicinal Chemistry
  75. Dual‐Knockout of Mutant Isocitrate Dehydrogenase 1 and 2 Subtypes Towards Glioma Therapy: Structural Mechanistic Insights on the Role of Vorasidenib
    Preantha Poonan, Clement Agoni, Mahmoud E. S. Soliman · 2021 · Chemistry & Biodiversity
  76. Conventional chondrosarcoma of the rib cage and sternum: clinicopathological and molecular analysis of 27 patients treated at a single institution
    Eman Abdulfatah, Douglas A. Rottmann, Yoav Morag, Liron Pantanowitz, Aaron M. Udager, Wei Hao, David Robert Lucas · 2023 · Human Pathology
  77. IDH1 p.R132 mutations may not be actively involved in the carcinogenesis of hepatocellular carcinoma
    Yong‐Gang Yao · 2014 · Medical Science Monitor
  78. Enchondromatosis-associated oligodendroglioma: case report and literature review
    Takamune Achiha, Hideyuki Arita, Naoki Kagawa, Tsuyoshi Murase, Jun‐ichiro Ikeda, Eiichi Morii, Yonehiro Kanemura, Yasunori Fujimoto, Haruhiko Kishima · 2017 · Brain Tumor Pathology
  79. TFE3 rearranged epithelioid hemangioendothelioma of bone: A clinicopathological, immunohistochemical and molecular study of two cases
    Huizhi Zhang, Lei Dong, Suying Wang, Xiaoqun Yang · 2020 · Annals of Diagnostic Pathology
  80. The presence of TIM‐3 positive cells in WHO grade III and IV astrocytic gliomas correlates with isocitrate dehydrogenase mutation status
    Mia Dahl Sørensen, Ole Nielsen, Guido Reifenberger, Bjarne Winther Kristensen · 2020 · Brain Pathology
  81. Enchondromatosis and Growth Plate Development
    Hongyuan Zhang, Benjamin Aaron Alman · 2020 · Current Osteoporosis Reports
  82. From Metabolism to Genetics and Vice Versa: The Rising Role of Oncometabolites in Cancer Development and Therapy
    Emanuela Di Gregorio, Gianmaria Miolo, Asia Saorin, Agostino Steffan, Giuseppe Corona · 2021 · International Journal of Molecular Sciences
  83. Early volumetric, perfusion, and diffusion MRI changes after mutant isocitrate dehydrogenase (IDH) inhibitor treatment in IDH1-mutant gliomas
    Nicholas S. Cho, Akifumi Hagiwara, Blaine S.C. Eldred, Catalina Raymond, Chencai Wang, Francesco Sanvito, Albert Lai, Phioanh Leia Nghiemphu, Noriko Salamon, Lori Steelman et al. · 2022 · Neuro-Oncology Advances
  84. Molecular profiling of sarcomas: new vistas for precision medicine
    Tariq Jassim Al-Zaid, Wei‐Lien Wang, Neeta Somaiah, Alexander J. Lazar · 2017 · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin
  85. Emerging therapeutic approaches for canine sarcomas: Pushing the boundaries beyond the conventional
    Antonella Borgatti, Erin B. Dickerson, Jessica Lawrence · 2019 · Veterinary and Comparative Oncology
  86. Synovial chondrosarcoma: a single‐institution experience with molecular investigations and review of the literature
    Marco Gambarotti, Marina Pacheco, Poosit Ruengwanichayakun, Brayan Vega Jiménez, Stefania Benini, Giuseppe Bianchi, Marta Sbaraglia, D. Vanel, Elisa Carretta, Franco Bertoni et al. · 2020 · Histopathology
  87. Implementing precision oncology for sarcoma patients: the CCCLMUmolecular tumor board experience
    Luc M. Berclaz, Anton Burkhard‐Meier, Philipp Lange, Dorit Di Gioia, M. Schmidt, Thomas Knösel, Frederick Klauschen, Michael von Bergwelt‐Baildon, Volker Heinemann, Philipp A. Greif et al. · 2023 · Journal of Cancer Research and Clinical Oncology
  88. IDH1/2 Mutations in Cancer: Unifying Insights and Unlocking Therapeutic Potential for Chondrosarcoma
    Shriya Deshmukh, Ciara Marie Kelly, Gabriel Tinoco · 2024 · Targeted Oncology
  89. Genomic Characterization of Chondrosarcoma Reveals Potential Therapeutic Targets
    Michael J. Wagner, Erica Maria Pimenta, Nathan W. Sweeney, Elizabeth T. Loggers, Jesse L. Roberts, Elyse J. Brinkmann, Eleanor Y. Chen, Robert W. Ricciotti, Candace L. Haddox, Rachel Berg et al. · 2025 · JCO Precision Oncology
  90. ‘The chicken or the egg?’ dilemma strikes back for the controlling mechanism in chordoma#
    Károly Szuhai, Pancras C.W. Hogendoorn · 2012 · The Journal of Pathology
  91. Current status of publicly available sarcoma cell lines for use in proteomic studies
    Xiaoqing Pan, Akihiko Yoshida, Akira Kawai, Tadashi Kondo · 2015 · Expert Review of Proteomics
  92. HIF-1α inhibits IDH-1 expression in osteosarcoma
    Deng-Cheng Liu, Xun Zheng, Yong Zho, Wanrong Yi, Zonghuan Li, Xiang Hu, Aixi Yu · 2017 · Oncology Reports
  93. 3‐(7‐Azaindolyl)‐4‐indolylmaleimides as a novel class of mutant isocitrate dehydrogenase‐1 inhibitors: Design, synthesis, and biological evaluation
    Yuanyuan Hu, Anhui Gao, Honghui Liao, Mengmeng Zhang, Gaoya Xu, Lixin Gao, Lei Xu, Yubo Zhou, Jianrong Gao, Qing Ye et al. · 2018 · Archiv der Pharmazie
  94. SPINT2 is hypermethylated in both IDH1 mutated and wild-type glioblastomas, and exerts tumor suppression via reduction of c-Met activation
    Fei Liu, Christopher D. Cox, Reshmi Chowdhury, Laura Dovek, HuyTram N. Nguyen, Tie Li, Sichen Li, Byram Hirsch Ozer, Arthur P. Chou, Nhung T. Nguyen et al. · 2019 · Journal of Neuro-Oncology
  95. SUMOylation Is Associated with Aggressive Behavior in Chondrosarcoma of Bone
    Jessie S. Kroonen, Alwine B. Kruisselbrink, Inge H. Briaire‐de Bruijn, Olaejirinde Olaniyi Olaofe, Judith V.M.G. Bovée, Alfred C.O. Vertegaal · 2021 · Cancers
  96. Hyperthermia as a Potential Cornerstone of Effective Multimodality Treatment with Radiotherapy, Cisplatin and PARP Inhibitor in IDH1-Mutated Cancer Cells
    Mohammed Khurshed, Èlia Prades-Sagarra, Sarah Saleh, Peter Sminia, Johanna W. Wilmink, Remco Jurriaan Molenaar, Johannes Crezee, Cornelis J.F. Van Noorden · 2022 · Cancers
  97. EZH2/hSULF1 axis mediates receptor tyrosine kinase signaling to shape cartilage tumor progression
    Zong-Shin Lin, Chiao-Chen Chung, Yu-Chia Liu, Chu-Han Chang, Hui-Chia Liu, Yung-Yi Liang, Teng‐Le Huang, Tsung-Ming Chen, Che‐Hsin Lee, Chih‐Hsin Tang et al. · 2022 · eLife
  98. Dedifferentiated chondrosarcoma of the larynx: Radiological, gross, microscopic and clinical features
    Kelly R. Magliocca, Mark A. Edgar, Amanda S. Corey, Craig R. Villari · 2017 · Annals of Diagnostic Pathology
  99. Measurement of Oncometabolites d-2-Hydroxyglutaric Acid and l-2-Hydroxyglutaric Acid
    Patricia M. Jones, Richard L. Boriack, Eduard A. Struys, Dinesh Rakheja · 2017 · Methods in molecular biology
  100. Intracranial Mesenchymal Chondrosarcoma Lacking the Typical Histopathological Features Diagnosed by HEY1-NCOA2 Gene Fusion
    Atsuhito Uneda, Kazuhiko Kurozumi, Atsushi Fujimura, Atsunori Kamiya, Takanori Hirose, Hiroyuki Yanai, Isao Date · 2020 · NMC Case Report Journal